##common.pageHeaderLogo.altText##

Technical comment

Vol. 155 No. 4 (2025)

Technical comment on: Würnschimmel C, et al. Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology

Cite this as:
Swiss Med Wkly. 2025;155:4069
Published
30.04.2025

Summary

No abstract available

References

  1. Würnschimmel C, Menges D, Kwiatkowski M, Sigg S, Prause L, Mattei A, et al. Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology. Swiss Med Wkly. 2024 May;154(5):3626. 10.57187/s.3626
  2. Takahashi T. Two conflicting guidelines on prostate specific antigen screening in Japan. Jpn J Clin Oncol. 2023 Mar;53(3):280–3. doi: https://doi.org/10.1093/jjco/hyac192
  3. Young RH, Eble JN. The history of urologic pathology: an overview. Histopathology. 2019 Jan;74(1):184–212. 10.1111/his.13753
  4. Totten RS. Some experiences with latent carcinoma of the prostate. Bull N Y Acad Med. 1953 Jul;29(7):579–82.
  5. Chodak GW, Schoenberg HW. Progress and problems in screening for carcinoma of the prostate. World J Surg. 1989;13(1):60–4. doi: https://doi.org/10.1007/BF01671155
  6. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet. 1994 Apr;343(8903):958–60. 10.1016/s0140-6736(94)90071-x doi: https://doi.org/10.1016/S0140-6736(94)90071-X
  7. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 1995 Nov;333(21):1401–5. 10.1056/NEJM199511233332107
  8. Swanson G. Survival and conservative treatment for localized prostate cancer. JAMA. 1996 Jan;275(1):31. doi: https://doi.org/10.1001/jama.1996.03530250035013
  9. Chodak GW. Comparing treatments for localized prostate cancer—persisting uncertainty. JAMA. 1998 Sep;280(11):1008–10. 10.1001/jama.280.11.1008
  10. Prasad V. Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. Am Fam Physician. 2015 Oct;92(8):678–80.
  11. Takahashi T. Determining the clinical significance of pathological findings in prostate cancer. Virchows Arch. 2024 Apr;: 10.1007/s00428-024-03804-w
  12. Harris E. Prostate Cancer Cases Might Rise to 3 Million Globally by 2040. JAMA. 2024 May;331(20):1698. 10.1001/jama.2024.6729